Use of Tirzepatide for Severe Reactive Hypoglycemia in a Patient with Obesity
Journal of Diabetes and Endocrine Practice · 01.04.2026 · 09 (02) · 212-214
DOI: 10.1055/s-0046-1817792 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes and Endocrine Practice, erschienen am 01.04.2026. Verfasst von Kamal Abouglila und 1 weiteren Autor:innen.
Abstract (Originalsprache)
AbstractReactive (postprandial) hypoglycemia is an under-recognized condition that can significantly impair quality of life. Standard management relies on dietary strategies, but refractory cases may require pharmacologic intervention. We describe a 35-year-old woman with class II obesity and recurrent symptomatic postprandial hypoglycemia (confirmed by Whipple's triad) refractory to diet modification and acarbose. Endocrine evaluation excluded insulinoma and other secondary causes. Off-label low-dose Tirzepatide was initiated, and continuous glucose monitoring performed after treatment showed substantially more stable glucose profiles and very few hypoglycemic events. The patient reported meaningful symptomatic improvement over the long term.
Zitieren
APA
Abouglila, K., & Gatnash, M. (2026). Use of Tirzepatide for Severe Reactive Hypoglycemia in a Patient with Obesity. Journal of Diabetes and Endocrine Practice, 09(02), 212-214. https://doi.org/10.1055/s-0046-1817792
Vancouver
Abouglila K, Gatnash M. Use of Tirzepatide for Severe Reactive Hypoglycemia in a Patient with Obesity. Journal of Diabetes and Endocrine Practice. 2026;09(02):212-214. doi:10.1055/s-0046-1817792
BibTeX
@article{Abouglila2026,
author = {Abouglila, Kamal and Gatnash, Mouad},
title = {Use of Tirzepatide for Severe Reactive Hypoglycemia in a Patient with Obesity},
journal = {Journal of Diabetes and Endocrine Practice},
year = {2026},
volume = {09},
number = {02},
pages = {212--214},
doi = {10.1055/s-0046-1817792}
}
EUVIMED